Commercialization
Signatera: Using Tumor DNA in Blood to Guide Treatment After Surgery
A tumor-informed blood test brings evidence of residual cancer into decisions about treatment after bladder-cancer surgery.
WEEKLY 004 · EDITION RECORD
Investing in What Comes After Discovery
Blood tests and treatment, cell preservation and receptor protection: the work of turning discoveries into usable technologies.
Contents
5 readingsR&D Allocation
Transporting Cell Therapies Without Refrigeration
ARPA-H's BoSS program is funding preservation materials and processes intended to let therapeutic cells withstand room-temperature storage.
Frontier Science
Different Causes, Similar Psychiatric Symptoms: Protecting the Receptor
Research on autoimmune psychiatric symptoms is informing treatments designed to protect receptors from pathogenic antibodies.
Commercialization
After AI Finds a Candidate, What Gets Paid For?
Experimental services and ownership of drug discovery assets offer different ways to earn revenue after AI identifies a candidate.
Commercialization
What Does Chugai Still See in a Drug Roche Is Walking Away From?
GYM329's planned return to SMA development may be a bid to build a different product proposition—not a reversal of the evidence on efficacy.
This issue’s insight: Investing in What Comes After Discovery →
Topic states at issuance
Memory resilience
Compare sleep, representational drift and selective synaptic perturbation to investigate changes compatible with memory.
- Next evidence
- Matched perturbations with different targets, fixed versus adaptive readout, and retention with or without relearning.
Shield: screening adoption
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
- Next evidence
- Track implementation, tests and payments, participation by previously unscreened people, and completed follow-up colonoscopies separately.
Therapy & companion diagnostics
Linked approval; uptake and payment open
- Next evidence
- Confirmatory evidence, payer policies covering the new use, and clinical adoption.
Compute for science
A collaboration route exists from Japan. Check funding, compute allocation, disclosure and IP conditions.
- Next evidence
- Check eligibility, collaborators, compute allocations, publication and IP terms. Deadline: December 1 at noon ET; decisions scheduled for March 1, 2027.
AI–scientist collaboration
Institutional report; independent verification open
- Next evidence
- Independent replication, public evaluation methods, and records of successes and failures from hypothesis to experiment.
After AI Finds a Candidate, What Gets Paid For?
ART function remains unknown. The article compares experimental services, joint discovery and contractual options exercised after validation.
- Next evidence
- Functional validation, contract terms, asset rights and allocation of failure risk.
Who Will Build the Systems to Oversee Clinical AI?
ARPA-H announced ADVOCATE development plans covering patient-facing AI, supervision, implementation and independent evaluation.
- Next evidence
- Missed errors, false alarms, appropriate clinical handoffs and evaluation in routine care.
How Far Can Human Neural Tissue Compensate for Lost Function?
A study examined human cortical organoid growth, connections, activity and behavior in mice with major developmental depletion of cortical and hippocampal excitatory neurons.
- Next evidence
- Manipulate graft activity during specific tasks to distinguish modulation of host circuits from information processing.
Can measuring brain function help us choose an antidepressant?
In SMART-D’s main analysis of 47 participants over eight weeks, selecting a marker-consistent drug did not demonstrate better outcomes.
- Next evidence
- Drug comparisons at the same treatment stage, and separate validation of early changes to inform subsequent decisions.
What Do New Cells Contribute to a Brain That Preserves Memories?
A human postmortem study suggested stalled neurogenesis associated with depression. A separate mouse study found that greater survival of new neurons improved discrimination of similar contexts.
- Next evidence
- Relate cell stage and circuit integration to memory retention, context discrimination and relearning.
Signatera: Using Tumor DNA in Blood to Guide Treatment After Surgery
Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
- Next evidence
- Track the authorized population and treatment conditions.
Transporting Cell Therapies Without Refrigeration
BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years.
- Next evidence
- Storage duration by cell type, recovered function and independent ATCC testing.
Different Causes, Similar Psychiatric Symptoms: Protecting the Receptor
Receptor-protection evidence spans cultured cells and animals; ART5803 has entered a Phase 2a patient trial.
- Next evidence
- Patient selection, CSF-inclusive assessment, and ART5803 safety and clinical outcomes.
What Does Chugai Still See in a Drug Roche Is Walking Away From?
As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
- Next evidence
- Patient selection, functional endpoints, long-term evidence and licensing terms.
Record format & provenance
The archive stores complete article text, public evidence references, event dates, scheduled/observed distinctions, topic states and disclosed series. It contains no mailbox identifiers or private email bodies.
Editorial record window: 2026-09-29 — 2026-09-30 / Method: editorial-events-v1